The EPS miss is notable but largely driven by non-cash warrant liability adjustments, not operational deterioration. The stock's primary driver remains the June 29 PDUFA decision on OLC. Traders should monitor for any FDA advisory committee meeting announcements or pre-PDUFA volatility. The strong cash position ($57.1M) reduces near-term dilution risk.
Price Chart
Executive Summary
Unicycive reported Q1 2026 EPS of -$0.54, significantly missing the consensus estimate of -$0.47, driven by a $4.8M non-cash charge from the change in fair value of warrant liability. The company's cash position strengthened to $57.1M, funding operations into 2027, while the key catalyst remains the June 29, 2026 PDUFA date for its lead drug candidate OLC.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP EPS of -$0.54 vs consensus -$0.47 (miss of 14.9%)
- Net loss of $12.8M vs net income of $0.5M in Q1 2025, primarily due to $4.8M non-cash warrant liability charge
- Cash, equivalents, and marketable securities of $57.1M as of May 11, 2026, up from $41.3M at year-end 2025
- PDUFA target action date for OLC NDA resubmission is June 29, 2026
- R&D expense decreased to $1.6M from $2.2M YoY; G&A expense increased to $6.8M from $5.8M YoY
- No revenue reported; pre-commercial stage company
Financial Impact
EPS miss of $0.07 vs consensus; net loss widened by $13.3M YoY due to non-cash warrant liability revaluation
Risk Factors
- FDA non-approval or Complete Response Letter for OLC on June 29, 2026
- Further dilution if additional capital is needed post-launch
- Warrant liability volatility could continue to distort reported earnings
- No approved products or revenue stream
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292698 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 3 | $4.22 | awaiting T+60 | — | $3.58 (−15.17%) |
Sep 29, 2026 28d ago | 8-K | $4.55 | awaiting T+60 | — | $3.58 (−21.32%) |
Aug 12, 2026 10w ago | 8-K | $5.39 | awaiting T+60 | — | $3.58 (−33.58%) |
Jul 2, 2026 16w ago | 8-K | $5.73 $4.81 | ▼ −16.06% | ▼ −19.06% | $3.58 (−37.52%) |
Jun 22, 2026 18w ago | DEFA14A | $7.87 $4.71 | ▼ −40.15% | ▼ −41.90% | $3.58 (−54.51%) |
Jun 16, 2026 19w ago | EFFECT | $7.17 $5.31 | ▲ +25.94% | ▲ +26.94% | $3.58 (+50.07%) |
Jun 5, 2026 20w ago | S-3 | $6.66 $5.05 | ▲ +24.17% | ▲ +27.23% | $3.58 (+46.25%) |
May 12, 2026 24w ago | 8-K | $8.17 $5.05 | ▼ −38.19% | ▼ −42.57% | $3.58 (−56.18%) |
May 12, 2026 24w ago | Press Release | $8.17 $5.05 | ▲ +38.19% | ▲ +42.57% | $3.58 (+56.18%) |
Apr 6, 2026 29w ago | 8-K | $6.62 $5.28 | ▼ −20.24% | ▼ −33.71% | $3.58 (−45.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers